

## Taiwan approves initiation of Ph 2 clinical trials of COVAXX's COVID-19 vaccine candidate

February 3, 2021 | News

**COVAXX is in production for the first 100 million doses, and subsequently over 500 million doses this year**



COVAXX, a U.S. biotechnology company and subsidiary of United Biomedical, Inc. (UBI), has announced that the Taiwan Ministry of Health and Welfare on January 29, granted conditional approval to begin Phase 2 trials of UB-612, its vaccine candidate to address the pandemic caused by SARS-CoV-2.

COVAXX is developing world's first multipeptide-based vaccine against COVID-19, using its high precision, commercially proven and scalable vaccine platform.

The Phase 2 clinical trial is a multi-center, placebo-controlled, randomized, observer-blind study to further explore the immunogenicity, safety, and tolerability of the UB-612 vaccine in three distinctive cohorts: adolescents (12 to 18 years old), adults (19 to 64 years old), and seniors (65 years and older). The first subject of the Phase 2 trials was enrolled last week, with the goal of completing enrollment and administration of the first doses of UB-612 in all subjects in one month. The total number of subjects to be enrolled is 3,850.

The clinical trial is set to be launched simultaneously in 11 medical centers and hospitals in Taiwan to accelerate the process of subject enrollment.

UB-612 is temperature stable at normal 2-8°C and does not need to be stored in an ultra-low temperature cold chain. COVAXX is in production for the first 100 million doses, and will deliver over 500 million doses this year.